Investigation into Inter-alpha Trypsin Inhibitor Heavy Chain 4 (ITIH4) as a biomarker for prenatal screening of Down syndrome using maternal plasma samples by Elliott-Friend, J.
The Plymouth Student Scientist, 2011, 4, (2), 3-29 
 
[3] 
 
 
Investigation into Inter-alpha Trypsin Inhibitor 
Heavy Chain 4 (ITIH4) as a biomarker for 
prenatal screening of Down syndrome using 
maternal plasma samples 
 
Jessica Elliott-Friend 
 
Project Advisor: Neil Avent, School of Biomedical & Biological Sciences, University 
of Plymouth, Drake Circus, Plymouth, PL4 8AA 
 
Abstract 
Background: Down Syndrome (DS) affects 3 per 1000 births and is a significant 
cause of fetal loss. Currently screening tests detect ~85% of affected pregnancies, 
with a 5% false-positive rate, whilst diagnosis requires invasive tests such as 
amniocentesis which is associated with a ~1% risk of miscarriage. More effective 
screening methods, or Non Invasive Prenatal Diagnosis (NIPD) methods, are 
required to reduce the need for invasive diagnostic tests.  
Aim: This study aims to investigate inter-alpha trypsin inhibitor heavy chain 4 (ITIH4) 
as a potential biomarker in DS pregnancies.  
Method: Samples include 8 non-pregnant controls and 7 pregnant women known to 
be carrying a DS fetus. 1D Western Blot analysis was carried out on all plasma 
samples, and 2D Western blot (2-DE) was subsequently carried out on samples of 
interest. Real-time PCR was undertaken to determine the sex of the fetuses.  
Results: 125kDa ITIH4 was identified in all samples using Western Blot analysis. 
ITIH4 is cleaved by kallikrein into a 35kDa fragment and a 100kDa fragment which is 
rapidly cleaved to yield a 70kDa fragment. Results for DS samples KC05 and KC06 
suggested only the 35kDa fragment was present, whilst all other samples 
demonstrated the presence of the full 125kDa ITIH4 protein, as well as the presence 
of the 35kDa fragment in some cases. DS samples KC01 and KC05 underwent 2D 
Western blot. Results for KC05 again only presented the 35kDa fragment, whilst 
KC01 presented both the fragment and full ITIH4 protein in contrast to the previous 
1D Western Blot which had only demonstrated the presence of the full ITIH4 protein.  
All DS fetal genders were successfully identified. 
Conclusion: ITIH4 was successfully identified using the 1D and 2D Western Blot, in 
all samples. Reasons for the presence of different fragment of ITIH4 in different 
plasma samples remain unclear and require further investigation. Further research 
needs to be undertaken to compare euploid samples with known trisomy samples on 
a larger scale to identify whether ITIH4 could be an effective biomarker in DS 
screening.  
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Introduction  
Down Syndrome (DS) occurs in 1-3 per 1000 births (including terminations) [1]. As 
25% of DS foetuses in the second trimester do not survive to term, the occurrence is 
significantly higher, with an even greater loss from the first trimester [2]. Currently, 
prenatal screening tests for DS involve assessing the levels of a combination of 
maternal serum markers, including human chorionic gonadotropin (hCG), 
pregnancy-associated plasma protein-A (PAPP-A) [3], alpha-fetoprotein (AFP)[4], 
inhibin A [5] and unconjugated estriol (uE3) [6] and measuring fetal nuchal 
translucency thickness using ultrasonography at 10-14 weeks gestation[3]. These 
methods have a detection rate of 80-87% and an associated 5% false-positive 
rate[7]. However, these methods are not diagnostic and a positive test means 
parents will be offered invasive procedures including amniocentesis after 15 weeks 
gestation or chorionic villus sampling (CVS) between 11 to 14 weeks gestation [8]. 
These invasive procedures are associated with an ~1% risk of miscarriage[9], 
potentially to a healthy fetus falsely diagnosed as at risk through current screening 
methods.  
Noninvasive Prenatal Diagnosis 
The risks associated with the invasive procedures described above highlights the 
need for early Noninvasive prenatal diagnosis (NIPD) that can be offered routinely as 
part of antenatal care [10]. After free fetal DNA (ffDNA) was shown to be present in 
maternal plasma and serum by Lo et al.,[11] using real-time PCR, and through 
advances in molecular techniques, the reality of using NIPD routinely is getting 
closer [10]. Nucleated red blood cells (NRBC), trophoblasts and CD34+ 
hematopoietic progenitors  have all been proven to be present within the maternal 
circulation, however, their application for clinical testing has been limited due to 
difficulties in reproducible techniques [12]. The methods for isolation of fetal cells, 
including Magnetic-based separation systems (MACS) and flow-sorting separation 
systems (FACS) also need to be improved before fetal cell analysis can have clinical 
applications [13].  
Dhallan et al., [14] identified two out of three DS samples, with fetal DNA 
distinguished from maternal DNA through single nucleotide polymorphisms (SNPs). 
Fetal DNA was enriched using formaldehyde [15][14]. However, there is a significant 
amount of controversy surrounding the efficacy of this method [16][17][18]. 
Nonetheless, Lo et al., [19] was able to use PCR amplification to determine the ratio 
of SNPs in PLAC4 mRNA (expressed by the placenta and transcribed from 
chromosome 21). From this it was possible to determine chromosome dosage 
(Figure 1) and determine DS in 90% of affected heterozygous fetuses. Fan et al., 
[20] sequenced ffDNA using high-throughput shotgun sequencing direcly from 
maternal plasma. Through this it was possible to measure the over and 
underrepresentaiton of the chromosomes in the fetus, this enabled 100% of DS 
fetuses to be detected. A significant advantage of these two methods is that they are 
polymorphism independent, unlike previous work by Dhallan et al., [14]. However, 
currently these methods have only been tested on a small scale. Chiu, et al., [21] 
has recently begun large scale validity trials that have used multiplexed maternal 
plasma DNA sequencing analysis to detect trisomy 21 fetuses with 97.9% specificity 
and 100% sensitivity, suggesting the suitability for them to be used clinically with the 
potential to reduce the need to invasive diagnostic procedures by 98%.  
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DS Biomarkers 
Whilst other methods involving ffDNA are improving, the use of biomarkers is still the 
current clinical method and therefore identifying proteins that are differentially or 
preferentially expressed in a disorder such as DS is useful for the development of 
rapid, sensitive and potentially diagnostic assays[22]. A complex interaction and 
balance of intracellular and extracellular signals affects the progression of pregnancy 
through to delivery, and it is thought that fetal abnormalities such as DS are able to 
disturb this balance [23]. Nagalla et al., [24] highlighted differences between protein 
abundance in DS serum samples when compared to the controls, within the first and 
second trimester. A long term goal of the Special Non-Invasive Advances in Fetal 
and Neonatal Evaluation (SAFE) Network of Excellence (NoE) is to identify a panel 
of biomarkers that are more informative than current DS markers, therefore 
increasing the detection rate and decreasing the need for invasive diagnostic tests. 
With the advances in proteomic techniques there is an opportunity to identify such 
biomarkers and improve prenatal screening or to potentially find diagnostic markers 
[10].  Michel et al., [25] identified 36/49 proteins from both amniotic fluid (AF) and 
maternal plasma, demonstrating that noninvasive methods of acquiring samples 
could become as useful as those obtained through invasive means and without the 
risks of unneccesary miscarriage. However, as described above current screening 
methods use serum and there is variation in the use of either plasma or serum 
across many studies involved in biomarker detection. Whilst serum has cells and 
clotting factors removed through clot formation, leaving just proteins and other 
molecules representative of the whole body system, plasma includes cellular 
material and clotting is prevented through the presence of anticoagulants such as 
EDTA [26].  
Several studies have used proteomic analysis on both serum and plasma to identify 
differentially expressed protein markers in DS. Kolialexi, et al., [27] analysed second 
trimester plasma samples using two-dimensional gel electrophoresis (2-DE) and 
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-
TOF-MS)  to identify nine differentially  expressed proteins. Whilst Tsangaris, et al., 
[28] identified seven proteins as differentially expressed in the second trimester of 
DS pregnancies compared with the control, again using 2-DE and MALDI-MS. 
However, this was carried out on amniotic fluid and therefore does not fulfil the role 
of a NIPD method, nonetheless it could be used to highlight potential biomarkers to 
investigate within maternal blood.  
Nagalla et al., [24] investigated the presence of biomarkers in maternal serum for 
both the first and second trimester, which could have a significant role in future early 
DS screening programmes. Fluorescence 2-D gel electrophoresis (2D-DIGE), 2-D 
liquid chromatography-chromatofocusing (2D-CF) and  MALDI-TOF-MS were used 
to identify over 50 proteins that were differentially expressed betweem DS and 
control pregnancies. Kolla et al., [29] used a more novel approach involving isobaric 
labelling (iTRAQ) in conjunction with mass spectrometry using MALDI TOF/TOF with 
plasma samples from the first trimester. This again, identified approximately 50 
proteins that were either up- or down- regulated in DS pregnancies. However, these 
were not all in conjunction with Nagalla et al [24]. These studies have all highlighted 
the ability to identify potential biomarkers, however, more large scale studies need to 
be carryed out to identify whether they could be used clinically. Nonetheless, Kolla et 
al., [29] and Nagalla et al., [24] identified inter-alpha trypsin inhibitor heavy chain 4 
(ITIH4) as being upregulated in DS pregnancies, with Nagalla et al [24] highlighting a 
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significant increase in DS pregnancies in both the first and second trimester. In 
contrast, Heywood et al., (Unpublished data) only found ITIH4 to be up-regulated in 
the second trimester using 2-DE on maternal plasma samples. Following evidence 
from these three studies, and the contrast in results, ITIH4 was identified as the 
potential biomarker that would be investigated within this study.  
ITIH4 
ITIH4, a 120kDa plasma protein [30], has been identified as an acute-phase protein 
(APP) in humans  and a member of the plasma protease inhibitor family [31], which 
is subject to cleavage by kallikrein [32]. Plasma kallikrein is synthesised in the liver 
as plasma prekallikrein, before being secreted into the blood and converting into 
plasma kallikrein [33] by factor XIIa [34]. When activated kallikrein, a serine 
protease, initiates the plasma kallikrein/kinin system [35] Cleavage of ITIH4 yields a 
100kDa and 35kDa fragment, with the 100kDa fragment rapidly cleaved to 70kDa 
[30] (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chromosome dosage.  Method of identifying the differences between normal and 
DS foetuses who are heterozygous at the SNP locus of PLAC4, which is transcribed by 
chromosome 21 and expressed from the placenta. PCR amplification was used to determine 
the ratio of SNPs in PLAC4. As the ratio of two alleles in a heterozygous euploid fetus would 
be 1:1 whereas in a trisomic fetus the ratio would be either 1:2 or 2:1. Using maternal 
plasma this ratio could be determined and the number of copies of chromosome 21 could be 
identified noninvasively [19]. 
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Figure 2.  Amino Acid Sequence of Human ITIH4. 70kDa fragment highlighted in green and 
the red section highlights the 35kDa fragment. Primary goat antibody (Abcam Ab92338) 
binds to region within 35kDa fragment that is highlighted in yellow (See materials and 
methods). (NCBI: NP_002209.2, Uniprot: Q14624) 
 
Aims & Objectives 
Ideally, biomarkers could be identified with an increased detection rate and 
decreased false-positive rate using methods including 2-DE, that improve the ability 
of screening programmes to identify DS pregnancies without the need for invasive 
procedures. Within this study, the presence of ITIH4 in DS pregnancies will be tested 
through the use of 1D Western Blot and 2D Western Blot (2-DE) analysis. In pigs 
ITIH4 expression increases in the endometrium in early pregnancy, with suggestions 
of a protective role as an APP for the uterus against an inflammatory response due 
to the conceptus attachment [32]. Whilst no research has been carried out on 
humans it suggests a possible role for this protein during pregnancy, and with the 
evidence above [24][29][Heywood et al., (Unpublished data)], a possible role as a 
prenatal screening marker for DS.  
 
Materials and Methods 
Samples  
Eight control blood samples (assumed to be non-pregnant) were obtained from the 
National Health Service Blood and Transplant (Filton, Bristol, U.K) with informed 
donor consent. Seven maternal blood samples, from pregnant females carrying a DS 
fetus, were obtained with informed consent from St Michael’s Hospital, Bristol, U.K. 
Maternal and gestational ages are shown in Table 1.  
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Table 1. Maternal and gestational age for DS pregnancy samples. N=7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Preparation  
Control blood samples were centrifuged at 3500rpm for 5 mins. The plasma was 
then removed and centrifuged again at 15000rpm for 15 mins at 4˚c. At least one 
aliquot from each sample had protease inhibitor cocktail (Sigma-Aldrich, Dorset, 
U.K.) added. Fractions were stored at -80˚c before analysis. Plasma from the DS 
samples was obtained through centrifugation of the blood samples for 10mins at 
4700rpm and followed by 15mins at 15500rpm. At least one aliquot from each 
sample had protease inhibitor cocktail added. Fractions were stored at -80˚c before 
analysis. 
Protein assay  
Protein concentrations determined using ‘Quick Start’ Bradford Protein protocol 
(Bradford (1976) Anal. Biochem. 72:248). Bradford assay reagent (Coomassie Blue 
G-250 100mg, Ethanol 50ml, Orthophosphoric acid 100ml, dH2O 850ml)(BioRad, 
Hertfordshire, U.K) used as blank with bovine serum albumin (BSA) for standard 
concentrations, 0.2-1.4mg/ml to form a standard curve. The absorbance of the DS 
plasma samples (1:100) were determined using the NanoVue Spectrophotometer, 
from this the concentration (mg/ml) of each sample was determined from the 
standard curve.  
Western Blot  
Preparation of 10% SDS-Polyacrylamide gel and gel run as per manufacturer’s 
instructions (Mini-PROTEAN Tetra Cell BioRad), 1x SDS-PAGE (BioRad) running 
buffer used. Gels were run at 200V for ~50minutes. Samples were heated at 100˚C 
for 5 minutes prior to being added to the well, with samples kept on ice at other 
times. 18.5µg of protein from DS samples were added to each well (see Table 2 for 
volume of sample added to each well) and 10µl of marker (HyperPAGE, Bioline) was 
added to each gel. Control samples added to Gel A (Figure 3) were 3µl plasma with 
9µl of sample buffer. Control samples added to Gel B (Figure 3) were 10µl of plasma 
+ 20µl HBSS, with 3µl of this mix added to 9µl sample buffer which demonstrates a 
much clearer results than that obtained through no dilution.  The proteins were then 
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blotted to an ImmobilonTM Transfer membrane (Millipore, Co Durham, U.K). The 
membrane was prepared by soaking in methanol for 15seconds before being 
transferred into H2O for 2 minutes. The filter paper and membranes were then 
soaked in blotting buffer. The blot was carried out using BioRad ‘Criterion’ Blotter as 
per manufacturer’s instructions. 1l Blotting buffer (14.4g 192mM glycine, 3.03g 
25mM, 200ml 20% Methanol) was pre-cooled prior to transfer. Gels were blotted at 
100v for ~35minutes before being blocked in 5% non-fat dried milk (Marvel) in 0.05% 
Tris Buffered Saline (TBS) Tween 20 with gentle agitation for 1-2hrs.  ITIH4 goat 
primary antibody (Abcam Ab92338) was then made up to a 1 in 500 dilution in 5% 
Marvel, and kept on the membrane with gentle agitation at 4˚C overnight (See Figure 
1 for binding site of antibody). After overnight incubation the membranes were 
washed in TBS Tween 20 before ITIH4 Rabbit anti-goat secondary antibody (Abcam 
Ab6741) was added (1 in 5000 dilution in TBS Tween), with gentle agitation for 2 
hours. Washed with TBS Tween 20, before a final wash with 1xTBS.  
 
Table 2. Concentration and volume of each maternal plasma sample to ensure equalised 
amounts of protein was added to each well (18.5µg) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Horseradish Peroxidase Blots  
Developer prepared as to manufacturer’s instructions (BioRad). 30ml of 1x HRP 
colour development buffer. 180µl HRP colour reagent B and 6ml of HRP colour 
reagent A (stored -20˚C) and kept in the dark. The developer was added to the 
membrane for ~15seconds and the reaction was stopped in H2O for 10 minutes.  
ECL Colour Development  
0.1ml/cm2 of ECL developer required from Chemiluminescence detection kit for HRP 
(EZ-ECL) (Geneflow, Staffordshire, U.K). Developer was incubated on the 
membrane for 2 minutes before images were captured, using the UVP EC3 Imaging 
system (Cambridge, U.K). Images were exposed for maximum of 25 seconds.  
Albumin/IgG Depletion 
KC01 and KC05 plasma samples were depleted of albumin/IgG using the 
Qproteome Albumin/IgG Depletion kit (Qiagen, Sussex, U.K) as per manufacturer’s 
Maternal Plasma 
Samples 
Concentration of 
samples after 
1:10 dilution 
(mg/ml) 
Volume added 
(µl) 
KC01 3.9 9.5 
KC02 2.3 16 
KC03 5.6 6.6 
KC05 7.4 5 
KC06 5.5 6.7 
KC06B 5 7.9 
KC09 4.7 7.4 
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instructions. Samples were diluted with phosphate buffered saline (PBS) then placed 
into the spin columns, which had been previously equilibrated with dilution buffer 
(50mM Tris·Cl; 4% (w/v) CHAPS; 200mM Urea, pH 7.5) suitable for 2-D PAGE 
analysis. The samples were shaken and incubated on at end-over-end shaker at 
room temperature for 5minutes. The flow-through, containing the depleted samples, 
from the spin columns were then collected by pulse centrifugation. The remaining 
protein within the spin column were collected by washing through with PBS and 
centrifugation as before.  
Two-Dimensional Western Blot (2-DE) 
Contaminants from the depleted samples were removed using 2’D Clean-Up kit (GE 
Healthcare, Little Chalfont, U.K.). 300µl of precipitant added to 100µl of depleted 
sample and vortexed for ~15seconds. The samples were then placed on ice for 15 
minutes before 300µl of co-precipitant was added and vortexed again. The samples 
were then centrifuged for 5 minutes, 13000rpm, 4˚c, and the supernatant removed. 
40µl of co-precipitant was added on top of the pellet and placed on ice for 5 minutes, 
before repeating centrifugation as previously described. De-ionised water was added 
to the pellet and vortexed, resuspending the protein, before 1ml of wash buffer and 
5µl of wash additive was added.  The sample was stored at -20˚c for 50minutes, with 
the samples vortexed at 10 minute intervals, before repeating centrifugation. The 
supernatant was then removed and rehydration buffer (7M urea, 2M thirourea, 2% 
CHAPS) added to each pellet. The sample was then vortexed before being placed at 
-20˚C overnight. 11cm IPG strips (pH 5-8) (GE Healthcare) rehydrated using 
rehydration solution (7M urea, 2M thirourea, 2% CHAPS, 0.002% Bromophenol blue, 
1% IPG Buffer pH3-10 (BioLyte, BioRad), 0.28% DTT) and subjected to isoelectric 
focusing, for 35-40k Volt hours, using 1x XT-Mops (BioRad) running buffer. Next, 
each strip was equilibrated with gentle agitation for 15 minutes with DTT equilibration 
buffer (Equilibration buffer (50mM Tris.HCl pH6.8, 6M Urea, 30% Glycerol, 5% SDS, 
bromophenol blue) + 0.02% DTT) before being rinsed with H2O. Then IAA 
equilibration buffer (Equilibration buffer + 0.0125% IAA) was added with gentle 
agitation for 15 minutes, as IAA is sensitive to light the strips were kept in the dark. 
IPG strips placed into precast SDS-PAGE gels (4-12% gradient)(BioRad) to undergo 
second dimension electrophoresis, (0.5W/gel, 40mA/gel, 120V max for 1.5hrs. 
4W/gel for 2.25hrs and 0.5W/gel for 0.25hrs). Either the gels underwent Western 
blot, which was carried out as previous method described, or gels were stained. 
When stained, the gels were firstly fixed in 10% Methanol/7% acetic acid for 10-30 
minutes. Next, the coomassie stain (0.1%, made up according to manufacturer’s 
instructions)(PhastGeltm Blue R)(GE Healthcare) was added, before they were 
destained in 25% methanol/10% acetic acid for one minute. Finally, the gels were 
destained overnight in 25% methanol. All images were gained using UVP EC3 
Imaging system.  
MS Profiling to determine identity of spots of interest  
Spots of interest (Figure 12) were obtained from the KC01 coomassie stained gel 
and sent for MS profiling by Dr Kate Heesom, Direct Proteomic Lab (Department Of 
Biochemistry, University of Bristol). 
Sex Determination - DNA Extraction and Real-Time PCR 
DNA extraction carried out using QIAamp Circulating Nucleic Acid kit (Qiagen) for 
1ml plasma samples by Dr Tracey Madgett. Real-time PCR carried out using qPCR 
guide (Eurogentec, Hampshire, U.K) as per manufacturer’s instructions. Y 
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chromosome specific DYS14 (Zimmermann et al., 2005) and SRY (Lo et al., 1998) 
used, alongside HBB (Lo et al., 1998), as positive control and H2O as negative 
control. All were HPLC purified and the PCR was carried out on the StepOne Plus 
(Applied Biosystems, California, USA). The PCR primers and probes(Table 3) 
(Eurofins MWG Operon, London, U.K) were in different concentrations (Table 4). 5µl 
of DNA was used for each well. The conditions for the PCR were 50˚C for 2 minutes, 
followed by 95˚C for 10 minutes and 50 cycles of 95˚C for 15 seconds and 60˚C for 1 
minute.  
 
Table 3. Primers and probes (Eurofins MWG Operon) used to determine the sex of the fetus 
within the maternal plasma samples. 
 
Table 4. Concentration (nM) of PCR Mixes used in for foetal gender determination on the 
real-time PCR 
 
 
 
 
 
 
 
 
 
  
  
PCR Mix Concentration (nM) 
  
Primer Probe 
DYS14 300 300 
SRY 300 300 
HBB 250 100 
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Results 
ITIH4 was identified as a potential new DS screening and/or diagnostic biomarker in 
several proteomic studies [24][29][Heywood, unpublished data]. Eight control plasma 
samples and seven maternal plasma samples, known to be carrying a DS fetus, 
underwent 1D Western blot analysis to determine the presence and expression of 
ITIH4. Information on gestational age and fetal sex were all determined to aid in 
analysis of the results.  
Western blot analysis of Control plasma samples  
Control plasma samples were analysed to determine whether ITIH4 is constitutively 
present in plasma (Figure 3). Samples underwent dilution as described in the 
materials and methods section. 10µl of each sample was added to the corresponding 
well, protein concentration was not determined. Both Gels A & B (Figure 3) show the 
presence of ITIH4 at 125kDa in all the plasma samples, as well as a smaller 
fragment, cleaved by kallikrein, demonstrated in some samples at around 35kDa. 
Western blot analysis of Maternal Plasma samples from known DS 
pregnancies 
 After Bradford Protein assay carried out to determine concentration of protein 
present in each sample, 18.5µg of protein added to each well in Gel A (Figure 4). Gel 
B (Figure 4) samples were diluted as previously carried out on Gel B (Figure 2). 
Results for both Gel A and B (Figure 4) demonstrate the presence of ITIH4 in all 
samples. However, KC05 and KC06 seemed to have little to none of the complete 
125kDa form of ITIH4. These gels also suggest that the remaining samples only 
have the full length ITIH4 with no 35kDa fragments present. The 
maternal/gestational age do not seem to correspond with the fragmentation pattern 
seen (Figure 4). A repeat experiment using the same methods, but in a different 
order to ensure that this had no effect on the results seen and to ensure no errors 
had been made with sample labelling, was carried out (Figure 5). Whilst more 
background noise was demonstrated than the previous results (due to different times 
between colour development and image acquisition), a much stronger result 
occurred. The presence of the 35kDa fragment was demonstrated to be present 
alongside the full ITIH4 in both samples KC06B and KC09, this was also found in 
Figure 6, using the ECL colour development procedure with a maximum exposure of 
25 seconds. All other results were in accordance with the results seen in Figure 4.  
Control Western Blot  
This blot was carried out using only Rabbit anti-goat secondary antibody to ensure 
that the results being seen are only due to binding of the primary antibody. Method 
carried out as previously described, without the primary antibody steps. Figure 6 
demonstrates some inappropriate binding of the secondary antibody. However, no 
binding has taken place within the areas of interest, 125kDa or 35kDa, and therefore 
the secondary antibody is not affecting the results that are being discussed. 
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Figure 3. Western Blot analysis of non-pregnant plasma samples. Aims to identify the 
presence of ITIH4 using goat primary antibody and rabbit anti-goat secondary antibody and 
a HRP colour development procedure, using 10% SDS-polyacrylamide gel. Samples added 
to Gel B were diluted. In both gels, 10µl of maternal plasma sample was added to each well. 
ITIH4 presence demonstrated at around 125kDa (red arrow) and a 35kDa (blue arrow) 
fragment 
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Figure 4. Western blot analysis of maternal plasma from known DS pregnancies to identify 
the presence of ITIH4 using goat primary antibody and rabbit anti-goat secondary antibody 
and a HRP colour development procedure.  18.5µg of protein added to each well in Gel A. 
Samples added to Gel B were diluted. Presence of ITIH4 demonstrated in all samples, with 
only the 35kDa fragment (blue arrow) present in samples KC05 and KC06. Red arrow 
highlights 125kDa region of full length ITIH4. Maternal and gestational age details given 
above sample numbers, does not suggest an association. 
Maternal age (yrs)   33        40            42           41        41          ----            36 
Gestational age      35        12+1      14+5      13+1        16         ----          19+6 
(Weeks) 
Maternal age (yrs)   33         40         42          41        41          ----       36 
Gestational age        35       12+1    14+5       13+1      16         ----       19+6 
(Weeks) 
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Figure 5. Repeat analysis of the DS pregnancy samples using Western Blot analysis and 
the HRP colour development procedure. 18.5µg of protein added to each well. 35kDa ITIH4 
fragment (blue arrow) present in KC06B, KC09, KC06 and KC05. Presence of ITIH4 
demonstrated in all samples. Red arrow highlights region of full length 125kDa ITIH4 
fragment 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Repeat analysis of the DS pregnancy samples using Western Blot analysis and 
the ECL colour development procedure. 18.5µg of protein added to each well. 25 second 
exposure. Demonstrates presence of ITIH4 in all samples 
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Figure 7.  Control Western Blot on DS pregnancy samples using only ITIH4 Rabbit anti-goat 
secondary antibodies. No binding has occurred in ITIH4 regions, 125kDa and 35kDa, red 
and blue arrows, respectively. Demonstrates the secondary antibody may be responsible for 
the background noise within our results 
 
Fetal Sex-determination using Real-time PCR  
Real-time PCR was carried out to determine whether the differences seen between 
the maternal plasma samples and the presence of the 35kDa fragment were due to 
the sex of the fetus. DNA was extracted from each sample, excluding KC01 due to 
insufficient volume. KC02 and KC06B samples had protease inhibitor added at the 
time of sample preparation. Table 5 gives the sex of the fetus for these samples, 
determined using both SRY and DYS14, with all results corresponding to both 
genes. As real-time PCR suggests KC05 was female (Figure 8) and KC06 male 
(Figure 9), and the 1D Western blot for these samples only presented the 35kDa 
fragment, it seems unlikely that the sex of the fetus is influencing ITIH4 
fragmentation.  
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Figure 8. Real-time PCR amplification plot for KC05 using DYS14 and SRY as Y 
chromosome markers (Purple and pink lines, respectively). Despite some contamination (red 
and green line), the plot suggests KC05 is female 
 
 
 
 
 
 
 
 
 
DYS14 
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Figure 9. Real-time PCR amplification plot for KC06 using DYS14 and SRY as Y 
chromosome markers (Purple and pink lines, respectively). Strong results for both DYS14 
and SRY demonstrated by the orange and green line, respectively, suggest that the fetus 
from sample KC06 is male 
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Table 5. Determination of fetal sex in each sample using Real-Time PCR and DYS14 and 
SRY as Y Chromosome specific markers 
 
 
 
 
 
 
 
 
 
2-DE analysis of maternal plasma samples KC01 and KC05 
2-DE was chosen as the next step in analysing some specified samples as it is a 
more sensitive method and has been used in many studies to identify biomarkers 
[24][27][28](Heywood et al, Unpublished data). Therefore, it was thought that this 
would give more detailed information on the differences being seen between two 
different DS pregnancy samples. KC01 and KC05 were chosen as Western Blot 
analysis had demonstrated that KC01 had only the full 125kDa ITIH4 present and 
KC05 had only the 35kDa fragment present. After albumin and IgG depletion, to 
remove abundant proteins that may mask the presence of the lower abundance 
ITIH4, 40µl of sample was added to hydrated IPG (pH5-8) strips. Four IPG strips 
underwent isoelectric focusing for 35-40k volt hours. Two strips underwent Western 
Blotting. The IPG strip was placed in pre-cast gels (4-12%) and the Western Blot 
was carried out as described previously, including HRP colour development (Figure 
10). The KC01 image in figure 10 demonstrates the presence of the 35kDa fragment 
as well as the full 125kDa ITIH4, which was unseen in the previous Western Blots. 
Supporting Figures 4 and 5, the results for KC05 using 2-DE (Figure 10) 
demonstrate the presence of the 35kDa fragment only. The remaining two gels were 
fixed and stained (see materials and methods).  
The coomassie stained gel for KC05 (Figure 11), suggests no 35kDa was present, in 
contrast to previous results (Figure 4 and 5), possibly due to low abundance of the 
ITIH4 fragment. Results for KC01 suggest presence of a protein around 125kDa, 
which may be ITIH4. In contrast to the 2D Western Blot carried out (Figure 10), but 
supporting the Western Blots depicted in Figures 4 and 5 no 35kDa fragment was 
found in the results for KC01. Figure 12 depicts superimposed images of KC01 from 
Figure 10 and KC01 from Figure 11, with regions highlighting the possible presence 
of ITIH4 on the Coomassie stained gel. However, slight differences demonstrated in 
the pl suggesting that it is not the presence of the full 125kDa ITIH4, as ITIH4 pI is 
6.51 (ExPASy http://expasy.org/cgi-bin/pi_tool) and the coomassie gel suggests the 
pI of the region suspected to be ITIH4 is greater than this.  
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Figure 10.  2-DE of KC01 and KC05. 40µl of sample added to hydrated IPG strip (pI 5-8). 
Isoelectric focusing undertaken over 35-30k volt hours. Strips added to precast gels (4-12%) 
before Western Blot and HRP colour development, demonstrates depletion has worked well. 
ITIH4 125kDa protein and 35kDa fragment identified in KC01. 35kDa fragment identified in 
KC05 
 
 
 
 
5 
5 pI 
KC05- 2D 
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Figure 11. 2-DE of KC01 and KC05 using Coomassie staining to highlight the most 
abundant proteins. Regions of interest depicted by arrows at 125kDa (red) and 35kDa (blue). 
No result depicted around 35kDa on the KC01 or KC05 coomassie gel, possibly due to high 
abundance proteins masking its presence. kC01 gel depicts spots and trail of protein around 
region of where the full 125kDa ITIH4 fragment would be expected 
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Figure 12. 2-DE of KC01 using 2D Western Blot image superimposed onto Coomassie stain 
image to determine region of ITIH4 on the Coomassie gel. Circle highlights ITIH4 identified 
through Western Blot analysis at 125kDa. Arrows highlighting coomassie stained spots that 
underwent MS analysis, as trail seemed to correspond with 2D Western gel image 
 
MS Profiling to Determine identity of Spots of interest from KC01 Coomassie 
stained gel  
This method is a high-throughput technique that only requires small amounts of 
protein (~0.1µg per MALDI spot) [24]. Therefore, this method was used to determine 
whether the spots within the coomassie stained KC01 gel, that seemed to 
correspond with the ITIH4 fragment, (Figure 12), was ITIH4. However, results found 
Complement component C3 was present in the analysed spots, possibly due to 
ITIH4 only being present in low abundance and therefore, not detected by the 
coomassie stain. Table 6 indicates the top four results gained from the MS analysis. 
The data indicates chain B was present however, when investigating, the known 
molecular weight (MW) for Complement component C3 Chain B (beta) was 71.3kDa 
with a theoretical pI of 6.82 (Expasy). This data does not correspond with the data 
outlined in Table 6, or from the results of the coomassie stain, which suggested the 
MW was similar to that of ITIH4, at around 125kDa. This suggested that the chain 
identified was Complement component C3 alpha chain, as the known MW is 
113.0kDa with a theoretical pI of 5.55 (Expasy) which is strongly supportive of the 
rank 1 result described in table 6.  
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Table 6. Proteins identified using MS and the suggested MW and pI. Protein scores >66 
indicate protein identity as significant (p<0.05) 
 
Discussion 
Through the use and addition of new maternal serum biomarkers, including PAPP-A 
and AFP, prenatal DS screening has rapidly evolved reducing the need for invasive 
procedures [24] including CVS that carry a small but significant ~1% risk of 
miscarriage [9]. With the occurrence of DS as much as 3 in 1000 births [1] increasing 
the detection rate from its current levels of 80-87% [7] is of significant importance to 
prenatal medicine and in particular for better non-invasive prenatal screening 
methods.  
Presence of ITIH4 
ITIH4 is a plasma glycoprotein secreted from the liver [38] and known to be present 
in plasma at concentrations of 80µg/ml [30]. Through the use of Western Blotting it 
has been possible to identify the presence of ITIH4 in all control and pregnant 
samples known to be carrying a DS fetus, as expected. However, the study would 
have been strengthened by an investigation into the concentration of ITIH4 present, 
to allow comparisons to be made between the concentration of ITIH4 in the pregnant 
and control samples and to identify any changes over the pregnancy. Nagalla et al., 
[24] used 2D-DIGE and 2D-CF to identify a 2.67 fold increase in ITIH4 in DS vs 
control samples in the first trimester and a 1.69 fold increase in the second trimester. 
These advances in proteomic separation technology allow much easier detection of 
differentially expressed proteins between samples and highlight the significant 
increase in information that can be obtained. However, this study was carried out on 
maternal serum, in contrast to our study, and therefore it may not be possible to use 
the study to suggest that this increase may have occurred in our samples. On the 
other hand, Kolla et al., [29], carried out a study on first trimester maternal plasma 
samples using iTRAQ and also found ITIH4 to be significantly upregulated (p< 0.001) 
in DS pregnancies compared to controls, suggesting ITIH4 is a potentially significant 
plasma and serum biomarker of DS. In contrast, Heywood et al., (Unpublished data) 
only found ITIH4 to be upregulated in maternal plasma samples carrying a DS fetus, 
in the second trimester, using 2-DE.    
 
 
Rank Protein Name 
Protein 
MW 
(kDa) 
Protein 
pI 
Protein 
Score 
Accession 
Number 
No’ of 
Peptide 
Hits 
1 
Chain B, Human 
Complement Component C3 
114.2 5.55 714 78101268 46 
2 
Chain B, Human 
Complement Component C3 
114.2 5.55 714 78101268 48 
3 
Chain B, Human 
Complement Component C3 
114.2 5.55 656 78101268 47 
4 
Chain B, Human 
Complement Component C3 
114.2 5.55 415 78101268 40 
The Plymouth Student Scientist, 2011, 4, (2), 3-29 
 
[24] 
 
ITIH4 as an Acute Phase Protein 
Although again based on serum biomarker proteins Nagalla et al., [24] suggested 
candidate biomarkers fall into three major functional groups; serum carrier proteins, 
protease inhibitors and acute-phase proteins. ITIH4 is related to a group of protease 
inhibitors, however, ITIH4 itself lacks the bikunin chain which contains the protease 
inhibitor domains [31]. Nonetheless, ITIH4 has been identified as a major acute 
phase protein (APP) in pigs [39] and cattle [40] and has been further characterised 
as a type II APP in humans  [31]. Pineiro et al., [31] observed a dose dependent 
upregulation of ITIH4 mRNA expression after exposure to interleukin-6 (IL-6) in 
hepatocarcinoma HepG2 cells, alongside an increase in secretion of the mature 
protein within the cellular media. This is significant as Licastro et al., [41] has 
demonstrated a significant increase in IL-6 levels in plasma of DS children, this is 
supported by Corsi et al., [42]. Whilst studies would have to be carried out to 
determine whether elevated levels of IL-6 occur prenatally this evidence suggests 
that the increase in ITIH4 in maternal serum and plasma in Down syndrome 
pregnancies may be caused by  an increase in plasma IL-6 levels within the fetus. 
Further research would be needed to determine whether the increased levels of IL-6 
amplifies expression of ITIH4 in the fetus which passes to the mothers blood 
resulting in the observations of Nagalla et al., [24] and Kolla et al., [29], or whether 
increased levels of IL-6 increase maternal expression of ITIH4.  
Limitations 
An important limitation of our study is the lack of maternal plasma samples  carrying 
known euploid fetuses, this places significant limitations on the conclusions that can 
be drawn from these results on the use of ITIH4 as a prenatal biomarker of DS. The 
use of maternal plasma samples from a known euploid fetus would be a benefit for 
comparisons to be made in a future study. The method could also be improved by 
including matched controls for factors including age, race and gestational age. As 
well as matching non-pregnant controls, which would attempt to remove any 
confounding factors. A further limitation, is the lack of information on the sex of the 
sample from KC01. Information on the sex of this sample would have been useful to 
see if it influenced the 2-DE results (Figure 10). Nonetheless, the results obtained 
from the Western Blots (Figure 4 and 5), and real-time PCR (Table 5) suggest that 
the sex of the fetus  had no effect on the differences seen between the samples.  
Kallikrein and ITIH4 
Kallikrein cleaves ITIH4 into a 100 and 35kDa fragment, with the 100kDa fragment 
subsequently cleaved to yield a 70kDa fragment [30]. The Western Blot analysis 
identified the 35kDa fragment and the full 125kDa protein. However, the full MW is in 
contrast to a number of other studies including [30], and Pineiro et al., [40] who 
found ITIH4 to have a MW of 120kDa. This may have been due to differences in the 
marker used. Nonetheless, the results for KC05 and KC06 suggested the full ITIH4 
molecule was not present. This is in contrast to the other results, from both control 
and pregnant samples, which found the full fragment to be present and in some 
cases, the 35kDa fragment aswel. No correlation was found between this result and 
the gestational or maternal age(Figure 4 and 5), or the sex of the fetus. 
A potential explanation for the fragmentation differences seen could be due to 
variations in kallikrein activity. Recently, Almeidaa, et al., [43] demonstrated that 
polymorphisms in the Angiotensin I-converting enzyme (ACE), II, ID and DD, 
affected plasma kallikrein activity. With the DD polymorphism associated with a 60% 
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and 30% increase in plasma kallikrein activity when compared with the II and ID 
polymorphisms, respectively. This may mean that an individual with a DD 
polymorphism has increased kallikrein activity which may result in more 
fragmentation of ITIH4, potentially resulting in the lack of full length 125kDa ITIH4 
seen in KC05 and KC06. However, this study has not been followed up by any other 
investigations and therefore it is unclear as to whether these results could be 
replicated.It is also possible the differences between the fragmentation patterns of 
the samples may be due to the type of samples  and how they were collected. For 
example, if serum was used instead of plasma, proteases, activated by the clotting 
process such as Kallikrein, may reveal different fragmentation patterns [38]. 
However, Song et al., [38] identified no alteration in fragmentation samples when 
using either serum or plasma from the same patient.  
Mass Spectrometry Analysis 
The MS analysis of the KC01 coomassie stained Gel (Figure 11) did not find ITIH4 to 
be present but complement component C3. This is likely to be due to the low protein 
concentration that was run on the gel which despite the protein depletion procedure 
meant there were more abundant proteins that masked the presence of ITIH4. If this 
study were to be carried out again then it would be useful to confirm the presence of 
ITIH4 and the methods could have been improved to reflect this, including running 
bigger IPG strips that would have allowed more protein to be added to the gel which 
would have been likely to yield the presence of the low abundance protein, ITIH4.  
The use of Proteomics 
Although proteomic separation technology has advanced, one of the major issues 
that hinders proteomic studies is the complex nature of the serum/plasma proteome, 
where many low abundance proteins are masked by the presence of a few highly 
abundant proteins [29], which has been highlighted in our study when it was not 
possible to identify the presence of ITIH4 after 2-DE, despite undergoing 
Albumin/IgG depletion. It is likely that this causes the large variation in results from 
different studies, which is further compounded by the variation in methods between 
studies [24]. ITIH4 also highlights the complication of post-translational modification 
including cleavage, which results in fragments that are present at an even lower 
concentration that the full protein, making detection increasingly difficult.  
Future directions 
Future work could focus on the ACE polymorphisms and plasma kallikrein activity, as 
to why we see the different fragmentation patterns, which may be completely 
independent of DS. It would be interesting to use another antibody to identify the 
presence the 70kDa fragment, to gain more information on how ITIH4 fragments. It 
would also be useful to investigate maternal plasma samples carrying known euploid 
foetuses, this would allow direct comparisons to be made on the cleavage patterns 
and to identify whether the cleavage patterns seen in DS samples KC05 and KC06 
only occur in DS samples. Need to carry out large-scale studies using similar 
methods to efficiently determine effective biomarkers.  
Conclusions 
This study has been unable to determine whether ITIH4 would be suitable as a 
biomarker in DS pregnancies. However, the presence of ITIH4 was determined in all 
control samples and maternal plasma samples known to be carrying a DS fetus, as 
expected. Variations were found in the fragment pattern of ITIH4 between DS 
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samples, which was not seen in the control samples. It is unclear as to what causes 
this variation, which was not associated with gestational or maternal age, or the fetal 
sex.  
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